Evidence map›Paper›PMID 28636795›Full record

Trial reportPsycho-oncology2018

Cancer-related disease factors and smoking cessation treatment: Analysis of an ongoing clinical trial.

Allison J Carroll, Anna K Veluz-Wilkins, Sonja Blazekovic, Ravi Kalhan, Frank T Leone, E Paul Wileyto, Robert A Schnoll, Brian Hitsman

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Psycho-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Adherence and Efficacy of Smoking Cessation Treatment Among Patients with COPD in China.International journal of chronic obstructive pulmonary disease
    Trial
  3. Review
  4. Article
  5. Adherence to Pharmacological Smoking Cessation Interventions: A Literature Review and Synthesis of Correlates and Barriers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Allison J CarrollNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0002-3576-8808
Anna K Veluz-WilkinsNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sonja BlazekovicUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Ravi KalhanNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Frank T LeoneUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
E Paul WileytoUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Robert A SchnollUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Brian HitsmanNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Northwestern University · USUniversity of Pennsylvania · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Behavioral Activation and Varenicline for Smoking Cessation in Depressed SmokersR01CA184211 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HITSMAN, BRIAN L · 2014 to 2018
$3.2M
Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical TrialR01CA165001 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SCHNOLL, ROBERT ADAM · 2012 to 2016
$3.0M
NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA165001NCI NIH HHS R01 CA184211
6 · The paper itself

Abstract

objectiveSmoking cessation treatment should be an important aspect of cancer care. In this study, we evaluated whether cancer-related disease factors adversely influence smoking cessation treatment.

methodsSmokers with cancer (within 5 years of diagnosis, any tumor site) were recruited for an ongoing trial of varenicline for smoking cessation. Disease factors, assessed at baseline, included tumor site, cancer treatment, time since diagnosis, and health-related quality of life. Medication adherence was defined by 132 of 165 pills taken and counseling adherence was defined by 4 of 4 behavioral counseling sessions attended. Abstinence was bioverified at Week 12. Using logistic regression analysis, we assessed the relationship between disease factors and 12-week medication adherence, counseling adherence, and abstinence.

resultsOf 144 participants, 56% were medication adherent, 74% were counseling adherent, and 39% were abstinent. Health-related quality of life predicted medication adherence (OR: 1.08, 95% CI, 1.01-1.16, P = .019, d = 0.20) but not counseling adherence or 12-week abstinence. Tumor site, cancer treatment, and time since diagnosis did not predict any smoking cessation treatment outcomes.

conclusionsCancer-related disease factors did not predict cancer survivors' engagement or success in smoking cessation treatment. Findings support National Comprehensive Cancer Network Clinical Practice guidelines that recommend smoking cessation treatment for all smokers with cancer, regardless of time since diagnosis.

Indexed as

AdultCounselingDrug MonitoringFemaleHumansLongitudinal StudiesMaleMedication AdherenceMiddle AgedNeoplasmsNicotinic AgonistsQuality of LifeSmokingSmoking CessationTreatment OutcomeVareniclineNicotinic AgonistsVareniclinecancercancer survivorsclinical trialoncologysmoking cessationtreatment adherencevarenicline

Identifiers

PMID28636795
PMCPMC5958302
OpenAlexW2660806622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.